吉非贝齐治疗难治性家族性高胆固醇血症和Ⅲ型高脂蛋白血症。
Gemfibrozil in the treatment of resistant familial hypercholesterolaemia and type III hyperlipoproteinaemia.
作者信息
Houlston R, Quiney J, Watts G F, Lewis B
机构信息
Division of Chemical Pathology and Metabolic Disorders, United Medical School, St Thomas' Hospital, London.
出版信息
J R Soc Med. 1988 May;81(5):274-6. doi: 10.1177/014107688808100512.
The efficacy of gemfibrozil in the treatment of resistant familial hypercholesterolaemia and type III hyperlipoproteinaemia was evaluated in 26 individuals over a mean period of 16 months. In the untreated state both disorders are associated with a high frequency of coronary heart disease. In the former, gemfibrozil with a bile acid sequestrant reduced plasma cholesterol by 32%, an incremental decrease of 17% compared with sequestrant therapy alone. In type III, plasma cholesterol was reduced by 40% and plasma triglyceride by 70%, while high-density lipoprotein cholesterol increased by 45%. In none of the patients studied did clinical or biochemical side effects occur.
在26名患者中对吉非贝齐治疗难治性家族性高胆固醇血症和III型高脂蛋白血症的疗效进行了平均为期16个月的评估。在未经治疗的状态下，这两种病症都与冠心病的高发病率相关。在前者中，吉非贝齐与胆汁酸螯合剂联合使用可使血浆胆固醇降低32%，与单独使用螯合剂治疗相比，额外降低了17%。在III型患者中，血浆胆固醇降低了40%，血浆甘油三酯降低了70%，而高密度脂蛋白胆固醇增加了45%。在所研究的患者中均未出现临床或生化副作用。
Zotero 插件